|
MBNL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.88178419700125E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.63125069008174E-12 |
| Normal-vs-Stage2 |
1.21014309684142E-14 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
2.252200E-01 |
| Stage1-vs-Stage3 |
5.693800E-02 |
| Stage1-vs-Stage4 |
9.596300E-03 |
| Stage2-vs-Stage3 |
8.662200E-01 |
| Stage2-vs-Stage4 |
2.848000E-01 |
| Stage3-vs-Stage4 |
2.744400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
5.26520000043718E-07 |
| Normal-vs-Asian |
1.74948944220432E-12 |
| Caucasian-vs-AfricanAmerican |
8.300100E-02 |
| Caucasian-vs-Asian |
5.655400E-01 |
| AfricanAmerican-vs-Asian |
2.853600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62592161956354E-12 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
8.915400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.68398628375144E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
<1E-12 |
| Normal-vs-Age(81-100Yrs) |
1.395340E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.757600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.078400E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.801000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.489560E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.149800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.531000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.255500E-03 |
| Classical-VS-Follicular |
5.571800E-01 |
| Classical-VS-Other |
7.150400E-01 |
| Classical-VS-Normal |
6.03961325396085E-14 |
| Tall-VS-Follicular |
2.306400E-02 |
| Tall-VS-Other |
2.909400E-01 |
| Tall-VS-Normal |
2.22044604925031E-16 |
| Follicular-VS-Other |
8.734400E-01 |
| Follicular-VS-Normal |
1.67199587508549E-12 |
| Other-VS-Normal |
2.424300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
1.62458935193399E-12 |
| N0-vs-N1 |
5.190400E-01 |
|
|
